|
|
|
|
| |
Elijah Alexander: ASH 2007: A Patient's Perspective
|
|
|
Elijah Alexander
Former NFL lineman and Myeloma Patient shares his reactions on attending ASH for the first time
|
|
|
|
 |
|
|
| |
Dr. Kyle: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
|
|
|
Dr. Robert Kyle
Mayo Clinic
Rochester, Minnesota
Chair, IMF Scientific Advisory Board
|
|
|
|
|
|
|
| |
Dr. Durie: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
|
|
|
Dr.Brian G.M. Durie
Cedars Sinai Cancer Center
Los Angeles, California
Chair of the International Myeloma Foundation
|
|
|
|
|
|
|
| |
Dr. San Miguel: A Review of Novel Agents Presented at the 49th Annual American Society of Hematology Meeting (ASH) 2007
|
|
|
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Gertz - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
|
|
|
Morie A Gertz, MD
Mayo Clinic
Rochester, Minnesota
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Boccadoro - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
|
|
|
Mario Boccadoro, MD
Divisione Universitaria di Ematologia
Ospedale Molinette
Torino, Italy
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
ASH 2007 INTERNATIONAL WEBCASTS
|
|
|
We are pleased to be able to present overviews of ASH 2007 in French, Spanish, German, Italian, Turkish, and Czech.
|
|
|
|
|
|
|
|
|
|
|
| |
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
|
|
|
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
|
|
|
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
|
| |
Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
|
|
|
Craig B. Reeder, MD
Mayo Clinic
Scottsdale, Arizona
|
|
|
|
|
|
|
| |
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
|
|
|
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
|
|
|
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
|
|
|
|
|
|
|
| |
Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
|
|
|
Anders Waage, MD
University Hospital
Trondheim, Norway
|
|
|
|
|
|
|
|
|
|
Relapsed/Refractory Myeloma:
|
|
|
| |
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
|
|
|
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
|
|
|
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
|
|
|
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas
|
|
|
|
|
|
|
| |
Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI
|
|
|
|
|
|
|
|
|
|
|
| |
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
|
|
|
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas
|
|
|
|
|
|
|
| |
Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
|
|
|
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain
|
|
|
|
|
|
|
| |
Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
|
|
|
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain
|
|
|
|
|
|
|
| |
Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
|
|
|
Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota
|
|
|
|
|
|
|
| |
Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
|
|
|
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
|
|
|
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
|
|
|
|
|
|
|
|
|
|
|
| |
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
|
|
|
Jean Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
|
|
|
Benedetto Bruno, MD, PhD
San Giovanni Battista Hospital
University of Torino
Torino, Italy
|
|
|
|
|
|
|
| |
Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
|
|
|
Roman Hajek, MD
University Hospital Brno
Brno, Czech Republic
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
|
|
|
Patrizia Tosi, MD
Serŕgnoli Institute of Hematology
Bologna, Italy
|
|
|
|
|
|
|
| |
Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
|
|
|
Meral Beksac, MD
Ankara University
Ibn Sina Hospital
Ankara, Turkey
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
|
|
|
Marco Ladetto, MD
Divisione Universitaria di Ematologia
L'universitŕ di Torino
Torino, Italy
|
|
|
|
|
|
|
| |
Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
|
|
|
Patrizia Tosi, MD
Serŕgnoli Institute of Hematology
Bologna, Italy
|
|
|
|
|
|
|
| |
Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
|
|
|
Javier de la Rubia, MD
University Hospital La Fe
Valencia, Spain
|
|
|
|
|
|
|
| |
Dr. Bladé - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
|
|
|
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
|
|
|
Peter Liebisch, MD
University Hospital of Ulm
Ulm, Germany
|
|
|
|
|
|
|
| |
Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of Würzburg
|
|
|
Hermann Einsele, MD
University Clinic of Würzburg
Würzburg, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
|
|
|
|
| |
Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
|
|
|
Orhan Sezer, MD
Medizinische Klinik und Poliklinik II
Berlin, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients
|
|
|
Herve Avet-Loiseau, MD
Institut de Biologie
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
|
|
|
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chair, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
|
|
|
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California
Chairman, International Myeloma Foundation
|
|
|
|
|
|
|
| |
Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
|
| |
Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI
|
|
|
|
|
|
|
| |
Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
|
|
|
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chairman, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
| |
Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
|
|
|
Hartmut Goldschmidt, MD
Medizinischen Universitätsklinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
|
|
|
|
button next to the volume control in the lower right hand corner.
